Stock Events

Stock Events

AIM ImmunoTech 

$1.1500
63
-$0.07-5.74% Thursday 21:00

Statistics

Day High
0.073
Day Low
0.0711
52W High
35.96
52W Low
0.0711
Volume
11,790
Avg. Volume
112,155
Mkt Cap
0
P/E Ratio
-
Dividend Yield
23.28%
Dividend
0.27

Upcoming

Dividends

23.28%Dividend Yield
May 26
$0.27
Nov 25
$0.27
May 25
$0.27
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-8
-5.36
-2.73
-0.09
Expected EPS
-0.135
Actual EPS
N/A

Financials

-10,188.24%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
340,000Revenue
-34.64MNet Income

Analyst Ratings

7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap25.69B
Incyte Corporation operates in the biopharmaceutical field focusing on the discovery, development, and commercialization of proprietary therapeutics, including those that affect the immune system's function, which competes with AIM's immunotherapy approaches.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including treatments that modulate the immune system, directly competing with AIM's product pipeline.
Moderna
MRNA
Mkt Cap58.11B
Moderna, Inc. focuses on mRNA-based therapies, some of which are designed to activate the immune system against cancer and infectious diseases, competing with AIM's immunotherapeutic strategies.
BioNTech
BNTX
Mkt Cap26.06B
BioNTech SE operates in the field of mRNA technology and immunotherapy, developing treatments that stimulate the body's immune response, similar to AIM's focus, making them direct competitors in the immunotherapy space.
Novavax
NVAX
Mkt Cap1.69B
Novavax, Inc. is involved in the development of vaccines that stimulate the immune system, competing with AIM ImmunoTech's efforts in immune system modulation for disease prevention and treatment.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.22B
Regeneron Pharmaceuticals, Inc. is known for its innovation in biotechnology, including the development of immune-modulating drugs, which places it in direct competition with AIM in the field of immunotherapies.
Cytodyn
CYDY
Mkt Cap315.04M
CytoDyn Inc. focuses on the development and commercialization of novel therapeutics for the treatment of immune, viral, and other serious diseases, competing with AIM's focus on immune-based therapies.
iBio
IBIO
Mkt Cap84.24M
iBio, Inc. is a biotechnology company that focuses on developing plant-based biopharmaceuticals, including vaccines and therapeutic proteins that modulate the immune system, making it a competitor to AIM in the broader field of immune-based therapies.

About

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Show more...
CEO
Thomas K. Equels
Employees
21
Country
United States

Listings

LSE
GB
0A4Y.LSE
F
DE
HXB.F
STU
DE
HXB.STU
MU
DE
HXB.MU

0 Comments

Share your thoughts

FAQ

What is AIM ImmunoTech stock price today?▼
The current price of AIMI is $1.15 USD — it has decreased by -5.74% in the past 24 hours. Watch AIM ImmunoTech stock price performance more closely on the chart.
What is AIM ImmunoTech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange AIM ImmunoTech stocks are traded under the ticker AIMI.
Is AIM ImmunoTech stock price growing?▼
AIMI stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year AIM ImmunoTech has showed a -55.25% decrease.
What is AIM ImmunoTech revenue for the last year?▼
AIM ImmunoTech revenue for the last year amounts to 340,000 USD.
What is AIM ImmunoTech net income for the last year?▼
AIMI net income for the last year is -34.64M USD.
Does AIM ImmunoTech pay dividends?▼
Yes, AIMI dividends are paid semi-annual. The last dividend per share was 0.27 USD. As of today, Dividend Yield (FWD)% is 23.28%.
How many employees does AIM ImmunoTech have?▼
As of September 09, 2026, the company has 21 employees.
In which sector is AIM ImmunoTech located?▼
AIM ImmunoTech operates in the Health & Wellness sector.
When did AIM ImmunoTech complete a stock split?▼
The last stock split for AIM ImmunoTech was on June 12, 2025 with a ratio of 1:100.
Where is AIM ImmunoTech headquartered?▼
AIM ImmunoTech is headquartered in OCALA, United States.